Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-11-19
2000-01-18
Sisson, Bradley
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 2, 530350, 530324, 435 691, A61K 3800
Patent
active
060157887
ABSTRACT:
The present invention provides polynucleotides which identify and encode a novel human nucleic acid binding protein (NABP). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding NABP. The invention also provides for the use of substantially purified NABP or its antagonists, in pharmaceutical compositions for the treatment of diseases associated with the expression of NABP. Additionally, the invention provides for the use of antisense molecules to NABP in pharmaceutical compositions for treatment of diseases associated with the expression of NABP. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of polynucleotides encoding NABP or anti-NABP antibodies which specifically bind to NABP.
REFERENCES:
patent: 5856128 (1999-01-01), Bandman et al.
Stryer, L. (1981) Biochemistry, WH Freeman and Company, New York, San Francisco.
Pang et al. (1993) GenBank Database, Accession No. S33706.
Zamore et al. (1994) GenBank Database, Accession No. S20250.
Fisher, D.E., et al., "Pulse labeling of small nuclear ribonucleoproteins in vivo reveals distinct patterns of antigen recognition by human autoimmune antibodies", Proc. Natl. Acad. Sci., 81:3185-3189 (1984).
Hermann, H., et al., "snRNP Sm proteins share two evolutionarily conserved sequence motifs which are involved in Sm protein-protein interactions", EMBO J., 14:2076-2088 (1995).
Kanaar, R., et al., "The Conserved Pre-mRNA Splicing Factor U2AF from Drosophila: Requirement for Viability", Science, 262:569-573 (1993).
Koren, E., "Murine and Human Antibodies to Native DNA That Cross-React with the A and D SnRNP Polypeptides Cause Direct Injury of Cultured Kidney Cells", J. Immunol., 154:4857-4864 (1995).
Lee, C.G., et al., "RNA Annealing Activity Is Intrinsically Associated with U2AF", J. Biol. Chem., 268:13472-13478 (1993).
Pang, Q., et al., "Two cDNAs from the plant Arabidopsis thaliana that partially restore recombination proficiency and DNA-damage resistance to E. coli mutants lacking recombination-intermediate-resolution activities", Nuc. Acids Res., 21:1647-1653 (1993).
Tsukahara, T., et al., "Regulation of alternative splicing in the amyloid precursor protein (APP) mRNA during neuronal and glial differentiation of P19 embryonal carcinoma cells" Brain Res., 679:178-183 (1995).
Zamore, P.D., et al., "Cloning and domain structure of the mammalian splicing factor U2AF", Nature, 355:609-614 (1992).
Hu, Y. et al., (GI 1809248) GenBank Sequence Database (Accession U51586) National Center for Biotechnology Information: National Library of Medicine, Bethesda, Maryland 20894 (Direct Submission) (1996).
Au-Young Janice
Bandman Olga
Hawkins Phillip R.
Hillman Jennifer L.
Incyte Pharmaceuticals Inc.
Longton Enrique D.
Sather Susan K.
Sisson Bradley
LandOfFree
Human nucleic acid binding protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human nucleic acid binding protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human nucleic acid binding protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-563427